Fracture risk following intermission of osteoporosis therapy

Dennison, E.M.; Cooper, C.; Kanis, J.A.; Bruyère, O.; Silverman, S.; McCloskey, E.; Abrahamsen, B.; Prieto-Alhambra, D.; Ferrari, Serge Livio; IOF Epidemiology/Quality of Life Working Group

doi:10.1007/s00198-019-05002-w

Scientific article

Review

English

Fracture risk following intermission of osteoporosis therapy

ContributorsDennison, E.M.; Cooper, C.; Kanis, J.A.; Bruyère, O.; Silverman, S.; McCloskey, E.; Abrahamsen, B.; Prieto-Alhambra, D.; Ferrari, Serge Livio; IOF Epidemiology/Quality of Life Working Group

Published inOsteoporosis International, vol. 30, no. 9, p. 1733-1743

Publication date2019

Abstract

Given the widespread practice of recommending drug holidays, we reviewed the impact of medication discontinuation of two common anti-osteoporosis therapies (bisphosphonates and denosumab). Trial evidence suggests the risk of new clinical fractures, and vertebral fracture increases when osteoporosis treatment with bisphosphonates or denosumab is stopped.

Keywords

Atypical fracture
Bisphosphonates
Denosumab
Drug holiday.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Génétique des ostéoporoses (544)

Citation (ISO format)

DENNISON, E.M. et al. Fracture risk following intermission of osteoporosis therapy. In: Osteoporosis International, 2019, vol. 30, n° 9, p. 1733–1743. doi: 10.1007/s00198-019-05002-w

Article (Published version)

Identifiers

PID : unige:134040
DOI : 10.1007/s00198-019-05002-w
PMID : 31175404

Commercial URLhttp://link.springer.com/10.1007/s00198-019-05002-w

ISSN of the journal0937-941X

256views

1downloads

Creation12/12/2019 1:42:00 PM

First validation12/12/2019 1:42:00 PM

Update time03/15/2023 9:27:19 PM

Status update03/15/2023 9:27:18 PM

Last indexation10/31/2024 6:21:40 PM

Archive ouverte UNIGE

Fracture risk following intermission of osteoporosis therapy

Technical informations